Brexit and REACH: what will the future hold?

NAHEED REHMAN | March 20, 2018

article image
It’s hard to avoid the topic of Brexit. It pervades almost everything we do both professionally and personally. In this post, we explore the uncertainties Brexit presents and how much energy is being spent in speculation about, as well as planning for, multiple possible outcomes. Like most companies associated with the chemical industry, a priority topic engaging the minds at Envigo is the impact of Brexit on REACH regulation. A quick read of the ECHA (European Chemicals Agency) website is sobering. It clearly states that, as it currently stands, if you are a UK-based registrant of a substance under REACH, once the UK leaves the EU, the registration will be perceived as 'non-existent'. Further reading shows the true extent of this existential crisis on future submissions.

Spotlight

Constellation Pharmaceuticals

Constellation Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel tumor-targeted and immuno-oncology therapies based on its pioneering research in cancer epigenetics. Founded in 2008 by seasoned scientific, medical and business leaders, Constellation was the first biopharmaceutical company to target selective regulators of epigenetic function as a potential therapeutic approach. Research at Constellation and by others has shown that modulating epigenetic regulation has the potential to be a powerful avenue for the development of breakthrough new medicines for cancer and other immune-mediated diseases.

OTHER ARTICLES

The multi-million dollar polymers opportunity: continued big regional price differentials

Article | June 29, 2021

POLYMER BUYERS outside northeast (NEA) and southeast Asia (SEA) have a big opportunity to save millions of dollars on procurement costs during the rest of this year through purchasing more from the two regions.The opportunity has arisen because I believe that NEA and SEA polymer prices will remain very cheap relative to most of the world until at least the end of 2021. NEA comprises China, Japan, Taiwan and South Korea. Our definition of the SEA region is Cambodia, Indonesia, Malaysia, Myanmar, the Philippines, Singapore, Thailand and Vietnam.NEA and SEA producers can also make a lot of money by constantly monitoring and acting on strong arbitrage opportunities in other regions. As supply disruptions in the US look likely to continue, Europe and South & Central America seem particularly good opportunities for both buyers and producers.Before we discuss why I see NEA and SEA remaining cheap relative to most of the rest of the world until at least the end of the year, let us consider in more detail the size of the prize, starting with the resin buyers.

Read More

The Potential Dangers Of Living Near A Chemical Plant

Article | February 21, 2020

Plant explosion may feel like a familiar news headline to Texans. But why? It's not the case in other areas of the country. Why do explosions seem so prevalent here? A straightforward reason for the unusual number of explosions in Texas is the type of industries that drive its economy. Texas is the nation's leader when it comes to petroleum refining and chemical product production. Refineries and production plants handle volatile chemicals. Without proper monitoring and safety measures, dangerous explosions can result.

Read More

Sustainability: A Core Initiative for Collaboration in the Chemical Industry

Article | February 19, 2020

Legislation and pressure from stakeholders are forcing the chemical industry to find efficiencies and urgently seek out ways to reduce environmental impact, such as implementing low-carbon initiatives, maximizing energy and water efficiency and developing new innovative products and processes. Last month’s World Economic Forum added further urgency as shareholders and investment groups added new sustainability criteria to their investment considerations. As the pressure to improve sustainability rises, organizations like SusChem, the European Technology Platform for Sustainable Chemistry, are gaining visibility and traction.

Read More

Petrochemicals markets complexity is only going to grow and grow

Article | May 13, 2021

NICE WORK, if you get can get it. A trucking company in Fort Worth, Texas, is offering to pay experienced drivers $14,000 a week – $728,000 a year – as the US struggles with a nationwide shortage of truckers or lorry drivers. This reminds me of perhaps an apocryphal tale, from the height of the last Australian mining boom. Before iron ore prices collapsed in late 2014, there was a story about workers at mining site road junctions who operated manual “Stop and Go” signs. They were said to be earning more than Australian dollar (A$) 200,000 a year. Before you pack in your job as, say, a petrochemicals sales manager and head to Texas or mine sites in Western Australia, there is the risk that when you arrive at the door of your new prospective employer, the bubble might have already burst. This is assuming we are in bubble conditions.The pressure is clearly building in petrochemicals and other commodity markets as prices in some regions remain at record highs or continue to rise. Today’s prices are the results of shortages of commodities supply (for example in petrochemicals, an outcome of the US winter storms), very strong demand and supply chain disruptions.I am beginning to believe that the latter is the biggest reason for commodity price inflation which is feeding through into sharp rises in the cost of finished goods – and a lack of goods availability. It is delivering and manufacturing enough stuff that seems to be at the heart of today’s problems due to shortages of everything from container freight space and semiconductors to wooden pallets, tin cans, metal drums, cardboard – and US truck drivers.

Read More

Spotlight

Constellation Pharmaceuticals

Constellation Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel tumor-targeted and immuno-oncology therapies based on its pioneering research in cancer epigenetics. Founded in 2008 by seasoned scientific, medical and business leaders, Constellation was the first biopharmaceutical company to target selective regulators of epigenetic function as a potential therapeutic approach. Research at Constellation and by others has shown that modulating epigenetic regulation has the potential to be a powerful avenue for the development of breakthrough new medicines for cancer and other immune-mediated diseases.

Events